In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
about
Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modificationIdentification and characterization of the human ARD1-NATH protein acetyltransferase complexRegulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemiaFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaThe molecular mechanisms of arsenic-induced cell transformation and apoptosis.The function, regulation and therapeutic implications of the tumor suppressor protein, PMLHow animal models of leukaemias have already benefited patientsA review of arsenic trioxide and acute promyelocytic leukemiaPIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemiaRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsArsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemiaComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesFactors determining sensitivity and resistance of tumor cells to arsenic trioxideSynergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studiesArsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET proteinEffect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxityRetinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemiaAnti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in ratsTargeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells.Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment.Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxideInteractions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments.CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment.Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyThe effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cellsArsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growthEssential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide.Arsenic trioxide - An old drug rediscovered.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxideBasic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells.Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.
P2860
Q24291154-7112229A-8CFD-4839-B26E-15E9D7E322BCQ24307878-9C6D8340-DA61-4A97-B58B-FCAF4F7FEA97Q24317497-DAC317E4-8C33-4391-8D93-427D6C55E91CQ24532901-467C8074-853F-4B32-80F4-DB8937E83D18Q24548302-47E8DE93-C8DC-4B83-9C3E-FE3012D24AD4Q24605527-F3E119CE-2147-41BF-92FB-68BC87D41EB8Q24812452-42B5B002-C145-41A6-9EF3-AB9DCC30876BQ26779358-DE0BE3DF-1286-4934-8B50-FAB2CE67209CQ26997702-76EAE8D9-62AB-484B-855A-5A7E30912175Q28087768-4086FCD0-B803-44E3-A62A-0726E7DB0C62Q28343393-87491016-92D6-4DDC-BBC5-33F5153B9185Q28344657-585F73EF-6969-48C0-9CAE-2AE972EFAF49Q28379542-99E15982-BEAE-4D32-9DE7-10C075A17A2CQ28397537-306F41B6-257C-436E-ABEE-02F0E8EFAA5FQ28483625-E0DF2DDD-E321-43D6-A263-1575A564104BQ28484167-CF6942E4-4DAA-4276-BECF-82B30F85F438Q28538642-630DABE2-A8DF-4FBB-871D-1A8CCF6FC5FAQ30921046-7F6F9C84-70DE-4B2F-BF29-57BA49DC5CC5Q33178068-DD107670-FD92-4D23-B02F-88CC70B2A913Q33226719-8A71951C-98FD-4E72-9911-4AAD30606F50Q33291299-90B40F59-98A0-44D3-A82E-58B8C4C51224Q33335885-1FE3CA7D-18D4-4B35-B5D9-284830DA610FQ33594955-A1155843-95CB-43FC-863E-702BE4B62C4AQ33628050-DE108BCD-F26C-41F6-B830-9162200F986AQ33640702-E8ABA570-D3E9-4E63-90F5-062EE4C484E2Q33665774-323FDFC5-73E6-4B71-AF75-53371C357C8EQ33726127-DB14DD73-1C54-476C-85FF-738AF9FD363AQ33791820-A4D7F670-CE3C-48DA-ACF8-13491AC598C5Q33850767-48C98B76-5D94-4527-A2C3-ECA723CF1A64Q33854193-FE45266F-999F-42C3-8206-B05DFE15EB75Q33962155-7CEAB7EF-403B-4924-8309-F8716CC3497CQ33965775-5F4E60BA-8F8B-484F-B96B-F6723FF9B7C5Q33976179-00202617-AC81-4302-BA72-2FD419E73B93Q34032925-316F7EF7-8F18-4856-93C1-E0AC20DA7260Q34054167-D9685897-1C1A-405E-A282-3E09C948D9AFQ34121354-2C52CEAC-7D7D-4DDB-97E1-24D41D779D3FQ34128180-F68E6823-0D67-4AC8-96D2-2ED77D9CCEDEQ34144553-8D24CA31-44D6-4CE8-B411-F83BAE571339Q34270770-B8721156-F256-4502-8969-2DA498663B5CQ34339982-FF9D2809-BA9A-48AD-A0F5-214154910A98
P2860
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@ast
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@en
In vitro studies on cellular and molecular mechanisms of arsenic trioxide
@nl
type
label
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@ast
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@en
In vitro studies on cellular and molecular mechanisms of arsenic trioxide
@nl
prefLabel
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@ast
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@en
In vitro studies on cellular and molecular mechanisms of arsenic trioxide
@nl
P2093
P1433
P1476
In vitro studies on cellular a ...... of PML-RAR alpha/PML proteins
@en
P2093
P304
P407
P577
1996-08-01T00:00:00Z